Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) CEO Robert Andrew Berman acquired 21,740 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were bought at an average cost of $1.15 per share, for a total transaction of $25,001.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
HJLI stock traded up $0.26 during trading hours on Friday, hitting $2.35. The company’s stock had a trading volume of 606,471 shares, compared to its average volume of 147,820. Hancock Jaffe Laboratories Inc has a 12 month low of $1.31 and a 12 month high of $5.64.
HJLI has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Hancock Jaffe Laboratories from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a research report on Friday, January 4th. ValuEngine downgraded shares of Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 21st.
Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc bought a new stake in Hancock Jaffe Laboratories in the third quarter worth approximately $141,000. Vanguard Group Inc. bought a new stake in Hancock Jaffe Laboratories in the third quarter worth approximately $141,000. Finally, Jane Street Group LLC bought a new stake in Hancock Jaffe Laboratories in the fourth quarter worth approximately $47,000. 1.79% of the stock is owned by institutional investors.
About Hancock Jaffe Laboratories
Hancock Jaffe Laboratories, Inc, a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease.
See Also: Quiet Period Expirations
Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.